The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Spawned numerous biotech companies that used it as a roadmap for their R&D.
But even the companies regarded as the cream-of-crop are at a disadvantage…
They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”
Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s overexpression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.
This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…
If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.
Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.
It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs.
Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price
News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.
This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another.
That is why I am recommending readers take a close look at it right now.
The company is currently eyeing a listing in other markets and a US listing may be on the horizon.
Article from Feb 23
Today I’m going to tell you about a revolutionary biotech startup that I previously tipped when it was trading at 2p back in November.
A company I believe is set to explode and has the potential to rise significantly in the near term.
What justifies such a bold prediction?
This company may hold the keys to the cure for aging...
The name of the company is Genflow Biosciences and it trades under the ticker (GENF) on the London stock exchange.
Consider that the biotech market is expected to reach USD 2.44 trillion by 2028 and expand at a CAGR of 15.83% until then.*
The demand for longevity is limitless, and the first companies that succeed in supplying the disruptive technologies that unlock it will capture the lion’s share of those trillions.
But before I go any further, let me ask you something…
Have you heard of the freshly minted biotech mega-startup that received $3 billion in backing in a single day?
According to Forbes, Altos Labs likely holds the world record for financing of any start-up by an order of magnitude or more.
With reports of early investments from entrepreneurial juggernaut Jeff Bezos and renowned info-tech investor Yuri Milner, Altos Labs is a likely contender for a top spot in the race to reverse aging and revolutionize medicine.
But backing from big names isn’t the only ace up the sleeve of Altos Labs…
The company has built an executive dream team of industry experts and scientific luminaries.
Among those reported to be joining the ambitious roster is none other than the Nobel prize winner for the discovery of reprogramming.
What is reprogramming and why is it important you might ask?
Shinya Yamanaka won his Nobel prize for discovering how to transform ordinary adult skin cells into any cell in the human body.
Need a new liver? Tired of living with Parkinson’s? Want your eyesight back?
Yamanaka’s research is key to engineering the regenerative medicine that will one day be responsible for replacing and repairing damaged organs and tissues.
With a deluge of capital and a hot shot team to employ it efficiently, Altos Labs is poised to accomplish its mission statement, “to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.”
But what does all of this have to do with Genflow Biosciences potentially significant rise in value?
I’m going to tell you, but first, let’s get some background.
Genflow Biosciences is challenging the aging process with exclusive patents to the leading longevity technology from the University of Rochester (US).
Okay, but why should we expect such sudden exponential growth.
The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...
To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spaw
so much more to come here. rns confirmation any time now the seller has completed her 14 million orderly market sell and then more on this
the completion of a detailed application dossier for the chemistry, manufacturing, and controls (cmc) of the group's medical treatment of nash. this will be presented to the belgian regulatory authorities (famhp/***g) in early june 2023.
the directors believe that this presentation is a significant milestone for the group, allowing it direct interaction with national regulatory authorities, and thus, paving the way for the group to commence clinical trials on an accelerated pathway (given there is currently no known medical treatment for nash).
· in collaboration with dr. manlio vinciguerra, (a company scientific advisory board member based at the university of liverpool), genflow has gained a significantly deeper understanding of the biochemical changes that occur in the treatment of nash using its centenarian sirt6. this research has led to the company clearly identifying the workings of its drug candidate and its potential benefits for nash patients. as a result, genflow has accumulated important data and is currently exploring additional ip opportunities.
Was at 5p when does started selling her holding down on a orderly market. That was 5p on news of application to list in USA, not we HAVE listed and news to come and most importantly for those that don't know , NO FUNDS REQD UNTIL 2025. So, 5p as a starter and then some. 10 million market cap is peanuts
Almost certain a NO from the fca regarding sandbox would have been communicated now.
They have given us the SANDBOX TESTING SCHEDULE for crying out loud. Without saying we've been accepted, GST have said they've been accepted.
Nothing can be made official until the bill goes thru tomorrow. Stock up, fill up, top up, whatever, but this is going to be massive